Guggenheim Reiterates Buy Rating on Rezolute, Inc.

Guggenheim maintains its buy rating on Rezolute, Inc. with an $11 price target.

Written by EarningsIQ · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 16, 2026, 5:03 PM EDT

Key Points

Guggenheim analyst Debjit Chattopadhyay reiterated a buy rating on Rezolute, Inc. with an $11 price target on June 15, 2026.
Rezolute, Inc. shares are trading at $4.00 with a market cap of $416.9 million, and it operates in the biotechnology sector.
Insiders, including CFO Daron Evans, have been active recently with both buying and selling transactions.

Guggenheim analyst Debjit Chattopadhyay has reiterated a buy rating on Rezolute, Inc. (NasdaqCM: RZLT) as of June 15, 2026. The firm maintained its price target of $11 for the biotechnology company, which is currently trading at $4.00.

Other Institutional Activity in Rezolute, Inc.

Several institutional investors have been adjusting their positions in Rezolute, Inc. Federated Hermes, Inc. reduced its holdings by 3,544,053 shares, ending with 12,990,659 shares valued at approximately $39.6 million. RA Capital Management, L.P. maintained its position with 9,180,000 shares worth about $28.0 million. BlackRock, Inc. trimmed its stake by 454,703 shares, leaving it with 6,313,503 shares valued at around $19.3 million. Meanwhile, Opaleye Management Inc. slightly increased its position by 12,844 shares to a total of 6,300,000 shares, valued at about $19.2 million. Balyasny Asset Management L.P. boosted its holdings by 541,560 shares, now holding 5,048,421 shares worth approximately $15.4 million.

Rezolute, Inc. Stock Snapshot

Shares of NasdaqCM: RZLT are trading around $4.00. Rezolute, Inc. has a market capitalization of approximately $416.9 million. The company has a forward P/E ratio of -6.91 and a beta of 0.65, indicating lower volatility compared to the market. The stock's 52-week low is $1.07, and its high is $11.46. It has a 50-day moving average of $3.48 and a 200-day moving average of $5.25. The company maintains a strong financial position with a current ratio of 15.84 and a quick ratio of 15.61, alongside a debt-to-equity ratio of 0.95.

Recent Earnings

Rezolute, Inc. is currently not profitable, with an EPS of -$0.81. The company has a net margin of 0.0% and a return on equity of -81.7%. Investors are looking forward to the next earnings report, scheduled for September 16, 2026.

Insider Buying and Selling at Rezolute, Inc.

Recent insider transactions include CFO Daron Evans purchasing 10,000 shares at an average price of $2.85 on March 30, 2026. CEO Nevan Elam sold 27,618 shares at $2.99 on March 2, 2026. Chief Medical Officer Brian Kenneth Roberts also sold 11,439 shares on the same day at $2.99. In earlier transactions, Roberts bought 28,000 shares at $1.70 on December 16, 2025, while Wladimir Hogenhuis purchased 5,650 shares at $1.69.

Analysts Set New Price Targets

On June 15, 2026, Guggenheim maintained its buy rating with an $11 target. Maxim Group also kept its buy rating on June 3, 2026, with a target of $14. The consensus among analysts is a buy recommendation, with a mean target price of $7.11 across nine opinions.

About Rezolute, Inc.

Rezolute, Inc. is a biotechnology company focused on treating rare diseases, particularly those related to hypoglycemia caused by hyperinsulinism. Headquartered in Redwood City, California, the company is led by CEO Nevan Charles Elam. Rezolute's key product, ersodetug, is in Phase 3 trials for treating congenital hyperinsulinism. Founded in 2010, Rezolute aims to improve outcomes for individuals with these challenging conditions.

Bottom Line

Guggenheim's reiterated buy rating on Rezolute, Inc. reflects confidence in the company's prospects. With a strong cash position and ongoing clinical trials, Rezolute remains a key player in the biotechnology sector. Investors should note that analyst ratings are based on past data and expectations, which may not reflect future performance.